Naproxcinod push deepens NicOx's losses
This article was originally published in Scrip
Executive Summary
NicOx's net loss more than doubled in 2008 as the company ramped up its spending in preparation of naproxcinod's commercial launch. The French firm's full-year loss widened to €73.9 million following a significant rise in R&D costs for the osteoarthritis drug.